A Study on the Safety, Absorption, and Elimination of Osivelotor (Radioactively Labeled With Carbon-14)
A Phase 1 Study to Assess the Mass Balance, Excretion, and Pharmacokinetics of [14C]-GBT021601, an Oral Hemoglobin S Polymerization Inhibitor, in Healthy Participants
Category & Conditions: Immune System Diseases and Conditions
Medicine: OSIVELOTOR
ClinicalTrials.gov Identifier (NCT): NCT05718687
Protocol ID: C5351003
Open Plain Language Summary Result:
Click here